DivestmentJul 13, 2026, 08:41 AM
Edgewise Completes $2.65B Sevasemten Sale; Shifts Focus to Cardio
AI Summary
Edgewise Therapeutics, Inc. announced the completion of the sale of its sevasemten compound and muscular dystrophy program to Servier Pharmaceuticals LLC and Les Laboratoires Servier. The transaction involved $1.55 billion in upfront cash and up to $1.1 billion in additional milestone payments, for a total potential consideration of $2.65 billion. This divestment strengthens Edgewise's balance sheet and allows the company to strategically focus on advancing its cardiovascular pipeline, with the upfront proceeds expected to fully fund EDG-7500 development through potential approval.
Key Highlights
- Edgewise Therapeutics completed the sale of its sevasemten compound and muscular dystrophy program to Servier.
- The transaction includes $1.55 billion in upfront cash consideration.
- Edgewise is eligible for up to $1.1 billion in additional milestone payments, totaling up to $2.65 billion.
- The company will now focus on its cardiovascular pipeline, including EDG-7500, EDG-15400, and EDG-003.
- Upfront proceeds are expected to fully fund EDG-7500 development through potential approval.
- A Phase 3 trial for EDG-7500 is expected to initiate in Q4 2026.
- Top-line data for the sevasemten GRAND CANYON pivotal trial is expected in Q4 2026.
Price Impact
More from EWTX